- Home
- MAX vs ORIC Comparison
MAX vs ORIC Comparison
Compare MAX & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAX | ORIC |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | 144 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.8M | 973.9M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MAX | ORIC |
|---|---|---|
| Price | $12.91 | $8.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $17.00 | ★ $19.50 |
| AVG Volume (30 Days) | 481.1K | ★ 1.3M |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,123,093,000.00 | N/A |
| Revenue This Year | $30.80 | N/A |
| Revenue Next Year | $9.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 64.86 | N/A |
| 52 Week Low | $7.33 | $3.90 |
| 52 Week High | $13.92 | $14.93 |
Technical Indicators
Market Signals| Indicator | MAX | ORIC |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 21.42 |
| Support Level | $12.60 | $10.45 |
| Resistance Level | $13.46 | $12.50 |
| Average True Range (ATR) | 0.53 | 0.73 |
| MACD | -0.06 | -0.24 |
| Stochastic Oscillator | 36.77 | 2.26 |
Price Performance
Historical ComparisonAbout MAX MediaAlpha Inc.
MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.